What is Zacks Research’s Forecast for Qiagen Q2 Earnings?

Qiagen N.V. (NYSE:QGEN) – Equities research analysts at Zacks Research cut their Q2 2026 earnings per share (EPS) estimates for Qiagen in a research report issued to clients and investors on Wednesday, May 27th. Zacks Research analyst Team now forecasts that the company will earn $0.61 per share for the quarter, down from their prior estimate of $0.63. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Qiagen’s current full-year earnings is $2.43 per share. Zacks Research also issued estimates for Qiagen’s Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.65 EPS, FY2026 earnings at $2.44 EPS, Q1 2027 earnings at $0.60 EPS, Q2 2027 earnings at $0.63 EPS, Q3 2027 earnings at $0.68 EPS, Q4 2027 earnings at $0.72 EPS, FY2027 earnings at $2.63 EPS, Q1 2028 earnings at $0.67 EPS and FY2028 earnings at $2.88 EPS.

A number of other brokerages have also commented on QGEN. JPMorgan Chase & Co. dropped their price target on Qiagen from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $59.00 price target on shares of Qiagen in a research note on Thursday, February 5th. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. UBS Group set a $52.00 price target on Qiagen in a research note on Monday, February 9th. Finally, Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the company a “hold” rating in a research report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.98.

Qiagen Stock Performance

Shares of QGEN stock opened at $36.15 on Thursday. The stock has a fifty day moving average of $37.86 and a 200 day moving average of $44.87. Qiagen has a 52 week low of $32.53 and a 52 week high of $57.81. The firm has a market capitalization of $7.45 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 3.54 and a beta of 0.64. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting analysts’ consensus estimates of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. During the same quarter last year, the firm posted $0.56 earnings per share.

Institutional Investors Weigh In On Qiagen

Several large investors have recently bought and sold shares of the business. Johnson Investment Counsel Inc. increased its holdings in Qiagen by 0.4% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock worth $2,563,000 after buying an additional 240 shares in the last quarter. Allworth Financial LP increased its holdings in Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after buying an additional 256 shares in the last quarter. Bessemer Group Inc. increased its holdings in Qiagen by 0.5% in the 3rd quarter. Bessemer Group Inc. now owns 51,780 shares of the company’s stock worth $2,288,000 after buying an additional 262 shares in the last quarter. Banque Cantonale Vaudoise increased its holdings in Qiagen by 1.8% in the 4th quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after buying an additional 290 shares in the last quarter. Finally, Commerce Bank increased its holdings in Qiagen by 4.9% in the 4th quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after buying an additional 314 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be issued a $0.35 dividend. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. Qiagen’s dividend payout ratio is 13.61%.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.